Trial Search Results
Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance
Patients will be enrolled based on presence of HCC and eligibility for TACE. They will be randomized to one of two arms for imaging navigation to the optimal catheter location for chemotherapy injection to treat the first (possibly sole) tumor target. The two arms will be: TACE using C-arm CT supplemented by DSA or DSA only (only DSA images will be used for navigation and tumor vessel tracking). Navigation to subsequent treatment targets in all patients will be done with fluoroscopy, CACT, and DSA, as is standard of care at Stanford University Medical Center, and is not part of the study. Vascular complexity, which affects navigation difficulty and thus the need for imaging, will be assessed separately for use in data analysis by two radiologists on a four-point scale.
Stanford is currently not accepting patients for this trial.
Collaborator: Siemens Healthcare Diagnostics Inc
- Device: C-arm CT + DSA as needed
- Device: DSA only
Patients must be affected by HCC
Patients must be 18 years old or older
Patients must have received an abdominal CT, PET/CT scan or MRI, completed prior to the
Ability to understand and the willingness to sign a written informed consent document.
Subjects under the age of 18
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study